2019 Cancer Genetics and Epigenetics GRC/GRS

2019年癌症遗传学和表观遗传学GRC/GRS

基本信息

  • 批准号:
    9754282
  • 负责人:
  • 金额:
    $ 0.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

Summary The 2019 Conference on Cancer Genetics and Epigenetics will focus on newly emerging aspects of the field including the genetic heterogeneity of cancer, the “long tail” of less frequent cancer mutations and the importance of intertumoral heterogeneity as assayed by single cell technologies. The importance of the non-coding genome in cancer will be highlighted as well as the rapidly evolving field of RNA epigenetics. Sessions on the lessons learned from genome wide surveys of cancer susceptibility as assayed by CRISPR screens and descriptions of cancer epigenomes will be complemented by talks on basic mechanism of gene regulation relevant to cancer and how genetically and epigenetically targeted therapies can be applied to specific tumor types. It has become increasingly apparent that the organization of the genome across temporal and spatial domains plays a large role in the control of cancer gene expression patterns and tumor biology and a session on the “4-D Nucleome” and cancer is planned. The large amounts of data generated by modern cancer genetic and epigenetic experiments require new modes of computational and systems analysis which will be discussed in sessions. This meeting should appeal to a wide range of cancer researchers and molecular biologists seeking to apply their work to cancer. In addition to an outstanding set of invited speakers there will be several interactive poster sessions, one-minute "poster preview" talks and several talks selected for platform presentation from the submitted abstracts.
总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan D. Licht其他文献

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl
肿瘤抑制因子 BRCA1 对细胞周期的抑制需要 CDK 抑制剂 p21WAF1/CiP1
  • DOI:
    10.1038/38291
  • 发表时间:
    1997-09-11
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Kumaravel Somasundaram;Hongbing Zhang;Yi-Xin Zeng;Yariv Houvras;Yi Peng;Hongxiang Zhang;Gen Sheng Wu;Jonathan D. Licht;Barbara L. Weber;Wafik S. El-Deiry
  • 通讯作者:
    Wafik S. El-Deiry
HLA-DR, CD33<sup>+</sup>, CD56<sup>+</sup>, CD16<sup>-</sup> Myeloid/Natural Killer Cell Acute Leukemia: A Previously Unrecognized Form of Acute Leukemia Potentially Misdiagnosed as French-American-British Acute Myeloid Leukemia-M3
  • DOI:
    10.1182/blood.v84.1.244.244
  • 发表时间:
    1994-07-01
  • 期刊:
  • 影响因子:
  • 作者:
    Amy A. Scott;David R. Head;Kenneth J. Kopecky;Frederick R. Appelbaum;Karl S. Theil;Michael R. Grever;l-Ming Chen;Michael H. Whittaker;Barbara B. Griffith;Jonathan D. Licht;Samuel Waxman;Margaret M. Whalen;Arthur D. Bankhurst;Lynn C. Richter;Thomas M. Grogan;Cheryl L. Willman
  • 通讯作者:
    Cheryl L. Willman
Compound Loss of <em>Dnmt3a</em> and <em>Kmt2c</em> in Myeloid Malignancies
  • DOI:
    10.1182/blood-2023-189411
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Prabhjot Kaur;Cassandra Berntsen;James Leonard;Daniil Shabashvili;Qingchen Yuan;Bowen Yan;Richard Lynn Bennett;Alberto Riva;Jonathan D. Licht;Olga A. Guryanova
  • 通讯作者:
    Olga A. Guryanova
Synergistic Effect of Trifluridine and PARPi Combination in Targeting <em>TP53</em>-Mutated AML
  • DOI:
    10.1182/blood-2024-201781
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Phani Krishna Parcha;Vivek M. Shastri;Jonathan D. Licht;Jatinder K. Lamba
  • 通讯作者:
    Jatinder K. Lamba
Sprouty1 Controls Genitourinary Development via its N-Terminal Tyrosine.
Sprouty1 通过其 N 端酪氨酸控制泌尿生殖系统的发育。
  • DOI:
    10.1681/asn.2018111085
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Vaquero;S. Cuesta;C. Anerillas;Gisela Altés;J. Ribera;M. Albert Basson;Jonathan D. Licht;J. Egea;M. Encinas
  • 通讯作者:
    M. Encinas

Jonathan D. Licht的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan D. Licht', 18)}}的其他基金

UF Health Cancer Center Support Grant - Training Navigator Supplement
佛罗里达大学健康癌症中心支持补助金 - 培训导航补充
  • 批准号:
    10892335
  • 财政年份:
    2023
  • 资助金额:
    $ 0.4万
  • 项目类别:
Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
探索 T 细胞急性淋巴细胞白血病中的 microRNA 降解
  • 批准号:
    10717486
  • 财政年份:
    2023
  • 资助金额:
    $ 0.4万
  • 项目类别:
University of Florida Health Cancer Center Support Grant
佛罗里达大学健康癌症中心支持补助金
  • 批准号:
    10625750
  • 财政年份:
    2023
  • 资助金额:
    $ 0.4万
  • 项目类别:
Developmental Funds
发展基金
  • 批准号:
    10625759
  • 财政年份:
    2023
  • 资助金额:
    $ 0.4万
  • 项目类别:
Leadership, Planning, and Evaluation
领导、规划和评估
  • 批准号:
    10625761
  • 财政年份:
    2023
  • 资助金额:
    $ 0.4万
  • 项目类别:
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
定义和针对黑色素瘤中表观遗传可塑性驱动的耐药性和免疫逃逸
  • 批准号:
    10666665
  • 财政年份:
    2022
  • 资助金额:
    $ 0.4万
  • 项目类别:
KDM6A mutation as an epigenetic driver of multiple myeloma
KDM6A 突变作为多发性骨髓瘤的表观遗传驱动因素
  • 批准号:
    10229675
  • 财政年份:
    2020
  • 资助金额:
    $ 0.4万
  • 项目类别:
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
MMSET 在淋巴恶性肿瘤发病机制和进展中的作用
  • 批准号:
    9330809
  • 财政年份:
    2016
  • 资助金额:
    $ 0.4万
  • 项目类别:
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
MMSET 在淋巴恶性肿瘤发病机制和进展中的作用
  • 批准号:
    9759647
  • 财政年份:
    2016
  • 资助金额:
    $ 0.4万
  • 项目类别:
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer
癌症中染色质的时空组织和信息传递
  • 批准号:
    8866966
  • 财政年份:
    2015
  • 资助金额:
    $ 0.4万
  • 项目类别:

相似国自然基金

基于CRISPR-Screen模型对肿瘤相关巨噬细胞通过GFRA1非经典途径促进胃癌肝转移的机制探索
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    54.7 万元
  • 项目类别:
    面上项目

相似海外基金

Differentiation-focused CRISPR Screen identifies LSD1 and Menin as combination therapy targets that induce terminal differentiation in AML
以分化为重点的 CRISPR 筛选将 LSD1 和 Menin 确定为诱导 AML 终末分化的联合治疗靶点
  • 批准号:
    10678478
  • 财政年份:
    2023
  • 资助金额:
    $ 0.4万
  • 项目类别:
CRISPR screenを利用したCLL-1.CAR-T細胞療法をブーストさせる因子の網羅的探索
使用 CRISPR 筛选全面寻找促进 CLL-1.CAR-T 细胞治疗的因素
  • 批准号:
    23K06750
  • 财政年份:
    2023
  • 资助金额:
    $ 0.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CRISPR screen to identify novel molecular mechanisms of HIV-1 latency
CRISPR 筛选鉴定 HIV-1 潜伏期的新分子机制
  • 批准号:
    22K07085
  • 财政年份:
    2022
  • 资助金额:
    $ 0.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CRISPR screen reveals novel target genes in prostate cancer
CRISPR 筛选揭示了前列腺癌的新靶基因
  • 批准号:
    22K20806
  • 财政年份:
    2022
  • 资助金额:
    $ 0.4万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Uncovering metabolic vulnerabilities of central nervous system leukemia using metabolic profiling of cerebrospinal fluid and an in vivo CRISPR screen
利用脑脊液代谢分析和体内 CRISPR 筛选揭示中枢神经系统白血病的代谢脆弱性
  • 批准号:
    457141
  • 财政年份:
    2021
  • 资助金额:
    $ 0.4万
  • 项目类别:
    Studentship Programs
Discovering Wdfy3 as a novel regulator of macrophage efferocytosis by genome-wide CRISPR screen
通过全基因组 CRISPR 筛选发现 Wdfy3 作为巨噬细胞胞吞作用的新型调节因子
  • 批准号:
    10606558
  • 财政年份:
    2020
  • 资助金额:
    $ 0.4万
  • 项目类别:
In vivo CRISPR screen to identify clinically relevant therapeutic targets for lung cancer
体内 CRISPR 筛选以确定肺癌临床相关治疗靶点
  • 批准号:
    421124
  • 财政年份:
    2020
  • 资助金额:
    $ 0.4万
  • 项目类别:
    Operating Grants
Discovering Wdfy3 as a novel regulator of macrophage efferocytosis by genome-wide CRISPR screen
通过全基因组 CRISPR 筛选发现 Wdfy3 作为巨噬细胞胞吞作用的新型调节因子
  • 批准号:
    10396543
  • 财政年份:
    2020
  • 资助金额:
    $ 0.4万
  • 项目类别:
CRISPR Screen Multiplexing for Uncharacterised Region Function (SMURF)
未表征区域功能的 CRISPR 多重筛选 (SMURF)
  • 批准号:
    2442270
  • 财政年份:
    2020
  • 资助金额:
    $ 0.4万
  • 项目类别:
    Studentship
Development of a new therapy for AML via CRISPR screen
通过 CRISPR 筛选开发 AML 新疗法
  • 批准号:
    19K17859
  • 财政年份:
    2019
  • 资助金额:
    $ 0.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了